Tysabri natalizumab: Post-marketing study data

Researchers at the University of California, San Francisco, reported data from a retrospective analysis of 84 MS patients who received >=12 infusions of Tysabri showing that 27.9% of patients who underwent a dosage interruption (n=68) experienced a clinical relapse within 6 months of the suspension, whereas no patients with ongoing treatment (n=16) experienced a flare during months 12-18 of treatment (p=0.017). Median time from treatment interruption to relapse onset was 3 months. Data were published in the Annals of Neurology. ...